A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

Trial Profile

A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Ganetespib (Primary) ; Sirolimus
  • Indications Nerve sheath neoplasms
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 02 Mar 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov.
    • 21 Aug 2015 According to ClinicalTrials.gov official title, patients minimum age, inclusion criteria and dose of Ganetespib have been revised.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top